high5oncology.tv | Meeting coverage | SABCS 2022

Diagnostics, CDK4/6i & ADC

SABCS 2022

E. Senkus, D. Lüftner, N. Harbeck, B. Pistilli, S. Paluch-Shimon

Part 1: Encouraging data that supports treatment...

RXponder; TAILORX

SABCS 2022

E. Senkus, D. Lüftner, N. Harbeck, B. Pistilli, S. Paluch-Shimon

Part 2: Treamtent options in high-risk breast cancer

SWOG S1207; monarchE; RIGHT choice

SABCS 2022

E. Senkus, D. Lüftner, N. Harbeck, B. Pistilli, S. Paluch-Shimon

Part 3: Testing for TROP-2 not needed / no prognostic...

TROPiCS-02

DESTINY-Breast02 & Breast03

SABCS 2022

D. Lüftner, A. Gennari, M. Untch, G. Guliano

Practice Changing ADC data confirmed

DESTINY-Breast 02; DESTINY-Breast 03

New Treatment Perspectives

SABCS 2022

W. Janni, N. Harbeck, V. Dieras, S. Tolaney, E. Ciruelos

New insights: Are CTCs predictive or not?

STIC CTC

SABCS 2022

N. Harbeck, E. Ciruelos, S. Tolaney, W. Janni, V. Dieras

SERDs - who benefits? ESR1 testing required?

EMERALD; SERENA-2

SABCS 2022

W. Janni, S. Tolaney, E. Ciruelos, V. Dieras, N. Harbeck

New treatment perspectives in luminal breast cancer

CAPitello-291; PACE

CDK4/6i, ADC, Pregnancy

SABCS 2022

A. Schneeweiss, A. Gennari, H. Rugo, P. Fasching

ADC: Do we need a target? Do we need a predicitve...

TROPiCS-02

SABCS 2022

A. Schneeweiss, A. Gennari, H. Rugo, P. Fasching

New evidence regarding the chance of pregnancies in EBC

POSITIVE

SABCS 2022

H. Rugo, A. Gennari, A. Schneeweiss, P. Fasching

monarchE confirms increasing benefit. What are the real...

monarchE

SABCS 2022

A. Schneeweiss, A. Gennari, H. Rugo, P. Fasching

RIGHT choice against Chemotherapy for aggressive...

RIGHT Choice

EBC Highlights

SABCS 2022

Karen Gelmon, MD

Good news for young patients

POSITIVE

SABCS 2022

Carmen Criscitiello, MD

POSITIVE-Trial shwos that temporal therapy interruption...

POSITIVE

SABCS 2022

Wolfgang Janni, MD

monarchE confirms data once more.

monarchE

SABCS 2022

Giuseppe Curigliano, MD

T-DXd as (neo)adjuvant treatment HR+/HER2- patients

TRIO-US B-12 TALENT

SABCS 2022

Diana Lüftner, MD

Interruption of endocrine therapy in case of desire to...

POSITIVE

SABCS 2022

Eva Ciruelos, MD

Benefit of extended adjuvant treatment with endocrine...

IDEAL

SABCS 2022

Eva Ciruelos, MD

Platin-based neoadjuvant therapy in early TNBC: impact...

SABCS 2022

Nadia Harbeck, MD

Time to reconsider Ki-67 threshold?!

monarchE

SABCS 2022

Sara Tolaney, MD

Adjuvant TH confirms excellent logn-term follow-up

APT

SABCS 2022

Eva Ciruelos, MD

First trial about pregnancy in premenopausal early BC...

POSITIVE

SABCS 2022

Nadia Harbeck, MD

Chemo without benefit in node-negative disease

TailorX

SABCS 2022

Andreas Schneeweiss, MD

Abemaciclib as standard of in high-risk HR+ HER2-...

monarchE

EBC highlights - Multilanguage

SABCS 2022

Eva Ciruelos, MD

El primer estudio sobre la gestación en pacientes con...

POSITIVE

SABCS 2022

Giuseppe Curigliano, MD

T-DXd as (neo)adjuvant treatment HR+/HER2- patients

SABCS 2022

Carmen Criscitiello, MD

POSITIVE-Trial dimostra che l'interruzione temporanea...

POSITIVE

SABCS 2022

Eva Ciruelos, MD

Neoadyuvancia con carboplatino en cáncer de mama precoz...

SABCS 2022

Eva Ciruelos, MD

Beneficio del tratamiento hormonal extendido según...

IDEAL

MBC highlights

SABCS 2022

Carmen Criscitiello, MD

SERENA-2 showed better PFS by camizestrant compared...

SERENA-2

SABCS 2022

Volkmar Müller, MD

Progress in research and clinic

ROSET-BM

SABCS 2022

Shani Paluch-Shimon, MD

A shift from chemotherapy to CDK4/6

RIGHT Choice

SABCS 2022

Alessandra Gennari, MD

Targeted approach for endocrine responsive visceral...

RIGHT choice

SABCS 2022

Shani Paluch-Shimon, MD

Highlights on oral SERDS in HR+ mBC

EMERALD; SERENA-2

MBC Highlights - Multilanguage

SABCS 2022

Shani Paluch-Shimon, MD

Highlights on oral SERDS in HR+ mBC

EMERALD; SERENA-2

SABCS 2022

Carmen Criscitiello, MD

SERENA-2 ha mostrato una migliore PFS grazie a...

SERENA-2

SABCS 2022

Alessandra Gennari, MD

Il miglior approccio per la malattia...

RIGHT choice

MBC highlights CDK4/6i

SABCS 2022

Volkmar Müller, MD

De-escalation in triple positive MammaCa

DETECT V

SABCS 2022

Diana Lüftner, MD

Endocrine combination despite visceral crisis

RIGHT Choice

SABCS 2022

Wolfgang Janni, MD

Ribociclib + endocrine in high risk HR+/HER2- MBC...

RightChoice

SABCS 2022

Elżbieta Senkus, MD

CDK4/6 inhibitors - a preferred option also for the...

RIGHT Choice

SABCS 2022

Sara Tolaney, MD

Continuing Palbociclib beyond progression does not...

PACE

SABCS 2022

Peter Fasching, MD

Treatment alternatives to chemotherapy for visceral...

RIGHT Choice

SABCS 2022

Volkmar Müller, MD

HR+/HER2-: Who still needs chemotherapy?

RIGHT Choice

SABCS 2022

Andreas Schneeweiss, MD

RIB + ET appears to be the better option than...

RIGHT Choice

MBC highlights CDK4/6i - Multilanguage

SABCS 2022

Elżbieta Senkus, MD

Inhibitory CDK4/6 opcją z wyboru również u chorych...

RIGHT Choice

MBC highlights ADC

SABCS 2022

Nadia Harbeck, MD

T-Dxd - ready for prime time in the 2nd line

DESTINY-Breast03

SABCS 2022

Veronique Dieras, MD

Important OS update for T-DXd

DESTINY-Breast03

SABCS 2022

Sara Tolaney, MD

Robust benefit of T-Dxd confirmed with new data

DESTINY-Breast02; DESTINY-Breast03

SABCS 2022

Andreas Schneeweiss, MD

Chemotherapy-free (neo)adjuvant treatment seems...

TRIO-US B-12 TALENT

SABCS 2022

Nadia Harbeck, MD

Great data - as usual with T-Dxd

DESTINY-Breast02

SABCS 2022

Andreas Schneeweiss, MD

T-DXd new standard after pretreatment with trastuzumab...

DESTINY-Breast03

DESTINY-Breast02

Andreas Schneeweiss, MD

T-DXd as therapy of choice even after T-DM1 in HER2+...

SABCS 2022

Volkmar Müller, MD

Optimal side effect management required

DESTINY-Breast02, DESTINY-Breast03

SABCS 2022

Karen Gelmon, MD

T-Dxd keeps us excited

DESTINY-Breast02; DESTINY-Breast03

SABCS 2022

Giuseppe Curigliano, MD

Positive data for ER+ and HER2+ breast cancer

EMERALD; SERENA-2; CAPItello-921; DESTINY-Breast 02; DESTINY-Breast 03

SABCS 2022

Javier Cortés, MD

TDXd is the prefered option for pts previously treated...

DESTINY-Breast02

SABCS 2022

Javier Cortés, MD

Clinically relevant and statistically significant...

DESTINY-Breast03

SABCS 2022

Elżbieta Senkus, MD

T-DXd with so far unkown efficacy

DESTINY-Breast02; DESTINY-Breast03

MBC highlights ADC - Multilanguage

SABCS 2022

Véronique Dieras, MD

Importante actualisation des données de survie globale...

DESTINY-Breast03

SABCS 2022

Giuseppe Curigliano, MD

Positive data for ER+ and HER2+ breast cancer

SABCS 2022

Javier Cortés, MD

TDXd es la primera opción para pacientes tratados...

DESTINY-Breast02

SABCS 2022

Elżbieta Senkus, MD

T-DXd – skuteczność, jakiej dotąd nie znaliśmy

DESTINY-Breast02; DESTINY-Breast03

SABCS 2022

Javier Cortés, MD

Beneficio clínicamente y estadísticamente significativo...

DESTINY-Breast03

MBC highlights SERD

SABCS 2022

Giuseppe Curigliano, MD

Positive data for ER+ and HER2+ breast cancer

EMERALD; SERENA-2; CAPItello-921; DESTINY-Breast 02; DESTINY-Breast 03

SABCS 2022

Barbara Pistilli, MD

A new drug in the endocrine landscape

EMERALD; SERENA-2

SABCS 2022

Karen Gelmon, MD

Oral SERDs are superior

EMERALD; SERENA-2; PACE

SABCS 2022

Wolfgang Janni, MD

oral SERDs on the rise?

EMERALD; SERENA-2

MBC highlights SERD - Multilanguage

SABCS 2022

Giuseppe Curigliano, MD

Positive data for ER+ and HER2+ breast cancer

SABCS 2022

Barbara Pistilli, MD

Una nouva molecola nel trattamento ormonale del tumore...

EMERALD; SERENA-2

SABCS 2022

Barbara Pistilli, MD

Une nouvelle molécule dans le traitement hormonal du...

EMERALD; SERENA-2

MBC highlights Varia

SABCS 2022

Wolfgang Janni, MD

Pregnancies after primary breast cancer

POSITIVE

SABCS 2022

Giuseppe Curigliano, MD

Positive data for ER+ and HER2+ breast cancer

EMERALD; SERENA-2; CAPItello-921; DESTINY-Breast 02; DESTINY-Breast 03

SABCS 2022

Diana Lüftner, MD

Estradiol withdrawal affects the micromillieu in the...

SABCS 2022

Alessandra Gennari, MD

Capivasertib - A drug for allcomers

CAPitello-291

SABCS 2022

Elżbieta Senkus, MD

Promising new player in the second line setting in...

CAPitello-291

SABCS 2022

Veronique Dieras, MD

CTC count may help in therapy decisions

STIC CTC

SABCS 2022

Peter Fasching, MD

AKT inhibitor capivasertib in HR+ mBC

CAPitello-291

SABCS 2022

Michael Untch, MD

ADC or other therapies after CDK4/6

EMERALD; SERENA-2; DESTINY-Breast 02; DESTINY-Breast 03

SABCS 2022

Peter Fasching, MD

Olaparib as an alternative to carboplatin in aggressive...

GeparOLA

SABCS 2022

Diana Lüftner, MD

Her2-low discordance rate at 40%

SABCS 2022

Wolfgang Janni, MD

Triple-positive MBC does not require chemotherapy.

DETECT V

SABCS 2022

Wolfgang Janni, MD

CTCs with metastatic breast cancer re-visited

STIC CTC

MBC highlights Varia - Multilanguage

SABCS 2022

Véronique Dieras, MD

Le compte des CTC peut orienter la décision...

STIC CTC

SABCS 2022

Giuseppe Curigliano, MD

Positive data for ER+ and HER2+ breast cancer

SABCS 2022

Alessandra Gennari, MD

Capivasertib un nuovo standard per tutti?

CAPitello-291

SABCS 2022

Elżbieta Senkus, MD

Obiecująca nowa opcja w drugiej linii zaawansowanego,...

CAPitello-291

eBC Year in Review

Year in Review 2022

N. Harbeck, A. Gennari, H. Rugo, E. Senkus

HR+ - Practice changing data - which therapy for which...

TailorX; ADAPT; monarchE; iSPY; POSITIVE; OlympiA

Year in Review 2022

N. Harbeck, A. Gennari, H. Rugo, E. Senkus

HER2+ - no new approval but long-term follow up data...

APHINITY; KAITLIN; perELISA; ADAPT; IMpassion050

Year in Review 2022

N. Harbeck, A. Gennari, H. Rugo, E. Senkus

TNBC - Practice changing data lead to new approvals -...

KEYNOTE-522; NACT Gupta et al.; OlympiA

mBC Year in Review

SABCS 2022

V. Diéras, R. Dent, C. Criscitiello, M. Untch

Dealing with Brain mets / Update TNBC

DESTINY-Breast02; DESTINY-Breast03; DETECT V; HER2CLIMB; TUXEDO-1; KEYNOTE-355

SABCS 2022

V. Diéras, R. Dent, C. Criscitiello, M. Untch

New Indications: ADCs & HER2-low

DESTINY-Breast02; DESTINY-Breast03; TROPICS-02; DESTINY-Breast04

SABCS 2022

R. Dent, V. Diéras, C. Criscitiello, M. Untch

The Right Choices? CDK4/6i vs. Chemo, SERDs & ESR1?

RIGHT Choice; MONARCH 3; PALOMA-2; EMERALD; AMEERA; acelERA BC